Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Rhythm Pharmaceuticals Inc

1RV
Current price
60 EUR -0.5 EUR (-0.83%)
Last closed 59.77 USD
ISIN US76243J1051
Sector Healthcare
Industry Biotechnology
Exchange Frankfurt Exchange
Capitalization 4 030 356 736 USD
Yield for 12 month +66.26 %
1Y
3Y
5Y
10Y
15Y
1RV
21.11.2021 - 28.11.2021

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 222 Berkeley Street, Boston, MA, United States, 02116

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

70.27 USD

P/E ratio

Dividend Yield

Current Year

+77 428 000 USD

Last Year

+23 638 000 USD

Current Quarter

+33 251 000 USD

Last Quarter

+29 078 000 USD

Current Year

+68 126 000 USD

Last Year

+21 505 000 USD

Current Quarter

+29 423 000 USD

Last Quarter

+25 954 000 USD

Key Figures 1RV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -263 916 000 USD
Operating Margin TTM -131.98 %
PE Ratio
Return On Assets TTM -46.24 %
PEG Ratio
Return On Equity TTM -147.9 %
Wall Street Target Price 70.27 USD
Revenue TTM 112 530 000 USD
Book Value 0.18 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 47.8 %
Dividend Yield
Gross Profit TTM 21 505 000 USD
Earnings per share -4.32 USD
Diluted Eps TTM -4.32 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin -230.11 %

Dividend Analytics 1RV

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 1RV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 1RV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 34.1557
Price Sales TTM 35.8158
Enterprise Value EBITDA -12.6462
Price Book MRQ 368.9616

Financials 1RV

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 1RV

For 52 weeks

29.38 USD 68.58 USD
50 Day MA 51.01 USD
Shares Short Prior Month 8 234 954
200 Day MA 45.1 USD
Short Ratio 19.99
Shares Short 8 460 312
Short Percent 20.98 %